G005599

LC/MS Analysis of Bile Acids and Their Conjugates on Ascentis^® Express C18

application for HPLC

Eigenschaften

• Methode(n): HPLC: suitable
• Testparameter: sample/matrix: Plasma proteins were removed with addition of 900 μL of acetonitrile, containing deuterated internal standards, to 250 μL of human EDTA plasma. The mixture was vortexed, (centrifuged and the supermatant evaporated before being reconstituted in a 50:50 solution of methanol and water. 10 μL (corresponding to 8.57 μL of plasma) was injected into the HPLC.); column: Ascentis Express C18, 15 cm x 4.6 mm I.D., 2.7 μm particles (53829-U); mobile phase: [A]: Water (5 mM ammonium acetate and 0.012% formic acid); [B]: Methanol (5 mM ammonium acetate and 0.012% formic acid); gradient: 70 to 95% B in 10 minutes held 4 minutes; flow rate: 0.6 mL/min; column temp.: 40 °C; detector: ESI(-), MRM Mode
• Eignung: application for HPLC
• Anwendung(en): clinical

Beschreibung

Hinweis zur Analyse

A fast robust LC-MS/MS method was developed on a C18 Ascentis Express Fused-CoreR Particle Column allowing the 15 bile acid species to be measured individually rather than the alternative measurement of a total concentration by colourimetric kinetic enzyme assays.

Rechtliche Hinweise

Ascentis is a registered trademark of Merck KGaA, Darmstadt, Germany

Analyt

Taurocholic acid sodium salt hydrate, ≥95% (HPLC)
Glycoursodeoxycholic acid, ≥96.0% (TLC)
Taurocholic acid (TCA)
Glycocholic acid hydrate, synthetic, ≥97% (HPLC)
Chenodeoxycholic acid
D4-Taurodeoxycholic acid (D4-TDC)
Sodium taurodeoxycholate hydrate, ≥95% (HPLC)
Ursodeoxycholic acid, ≥99%
Sodium glycochenodeoxycholate
Glycodeoxycholic-2,2,4,4-d₄ acid, ≥98 atom % D, ≥98% (CP)
Glycodeoxycholic acid monohydrate, ≥97% (TLC)
Cholic acid, from bovine and/or ovine, ≥98%
Sodium taurolithocholate
Glycolithocholic acid (GLC)
Chenodeoxycholic acid (CDC)
D4- Deoxycholic acid (D4-DC)
Deoxycholic acid, ≥98% (HPLC)
Lithocholic acid, ≥95%
Alle anzeigen (18)